AMERICAN KRATOM ASSOCIATION ASKS FDA COMMISSIONER CALIFF TO CONVENE A PUBLIC STAKEHOLDERS MEETING ON KRATOM POLICY
View full letter to Dr. Califf here
The American Kratom Association (AKA) today called upon FDA Commissioner Robert Califf, M.D. to convene a public stakeholder meeting on kratom regulatory policies of the FDA. The AKA’s letter to Commissioner Califf called out the fact the FDA itself has, in an official court document, stated that the Agency has “not yet made a determination regarding whether kratom is dangerous.”
The FDA has waged a persistent war on kratom, including making unsupported claims in official publications in the Federal Register that kratom’s main alkaloids pose an imminent hazard to public safety. (see Factor 6. What, if any, Risk is There to the Public Health). In addition, the current FDA and Kratom website contains outdated, inaccurate, and scientifically unsupportable claims about the purported dangers of kratom use. (see FDA & Kratom Page)
“It is our sincere hope that Commissioner Califf will see the importance of a public stakeholder meeting where conflicts in the Agency’s policy on kratom and the current science and policy landscape can be fully evaluated in the context of consumer experiences, advocacy groups, legal experts, and scientists in a two-way engagement on the best regulatory policy on kratom,” stated Mac Haddow, Senior Fellow on Public Policy for the AKA.
Link to the September 4, 2024, AKA letter to Commissioner Califf
